Zenas BioPharma, Inc. (ZBIO): R&D Expense
$168.06M
Year ended 2025-12-31
$213.47M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $168.06M | +20.8% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $139.14M | +131.8% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $60.03M | n/a | 2025-03-11, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $73.97M | +25.3% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $681.81M | +23.9% |
Compare ZBIO, JANX, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗